nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Cyclosporine—rheumatoid arthritis	0.551	1	CiPCiCtD
Vemurafenib—ALB—rheumatoid arthritis	0.0845	1	CbGaD
Vemurafenib—ALB—Auranofin—rheumatoid arthritis	0.0344	0.14	CbGbCtD
Vemurafenib—ABCG2—Leflunomide—rheumatoid arthritis	0.0321	0.131	CbGbCtD
Vemurafenib—ABCC1—Cyclosporine—rheumatoid arthritis	0.0225	0.0918	CbGbCtD
Vemurafenib—ABCG2—Sulfasalazine—rheumatoid arthritis	0.0199	0.081	CbGbCtD
Vemurafenib—ABCG2—Hydrocortisone—rheumatoid arthritis	0.0159	0.065	CbGbCtD
Vemurafenib—ABCG2—Cyclosporine—rheumatoid arthritis	0.015	0.0614	CbGbCtD
Vemurafenib—CYP1A2—Leflunomide—rheumatoid arthritis	0.0133	0.0541	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—rheumatoid arthritis	0.0119	0.0486	CbGbCtD
Vemurafenib—ALB—Prednisone—rheumatoid arthritis	0.0109	0.0447	CbGbCtD
Vemurafenib—ABCG2—Dexamethasone—rheumatoid arthritis	0.00991	0.0404	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—rheumatoid arthritis	0.00796	0.0325	CbGbCtD
Vemurafenib—CYP3A4—Ergocalciferol—rheumatoid arthritis	0.00768	0.0313	CbGbCtD
Vemurafenib—CYP3A4—Methylprednisolone—rheumatoid arthritis	0.00566	0.0231	CbGbCtD
Vemurafenib—ALB—Methotrexate—rheumatoid arthritis	0.00549	0.0224	CbGbCtD
Vemurafenib—CYP2D6—Cyclosporine—rheumatoid arthritis	0.00511	0.0209	CbGbCtD
Vemurafenib—CYP3A4—Triamcinolone—rheumatoid arthritis	0.00429	0.0175	CbGbCtD
Vemurafenib—CYP3A4—Betamethasone—rheumatoid arthritis	0.00368	0.015	CbGbCtD
Vemurafenib—CYP3A4—Prednisolone—rheumatoid arthritis	0.00363	0.0148	CbGbCtD
Vemurafenib—CYP3A4—Hydrocortisone—rheumatoid arthritis	0.00344	0.0141	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—rheumatoid arthritis	0.00343	0.014	CbGbCtD
Vemurafenib—CYP2D6—Dexamethasone—rheumatoid arthritis	0.00337	0.0137	CbGbCtD
Vemurafenib—CYP3A4—Cyclosporine—rheumatoid arthritis	0.00325	0.0133	CbGbCtD
Vemurafenib—CYP3A4—Dexamethasone—rheumatoid arthritis	0.00214	0.00874	CbGbCtD
Vemurafenib—Etoricoxib—PTGS2—rheumatoid arthritis	0.000312	1	CrCbGaD
Vemurafenib—Weight decreased—Dexamethasone—rheumatoid arthritis	0.000103	0.00186	CcSEcCtD
Vemurafenib—Dysgeusia—Cyclosporine—rheumatoid arthritis	0.000102	0.00185	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Azathioprine—rheumatoid arthritis	0.000101	0.00183	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Leflunomide—rheumatoid arthritis	0.000101	0.00182	CcSEcCtD
Vemurafenib—Eye disorder—Hydrocortisone—rheumatoid arthritis	9.97e-05	0.0018	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Betamethasone—rheumatoid arthritis	9.95e-05	0.0018	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Dexamethasone—rheumatoid arthritis	9.95e-05	0.0018	CcSEcCtD
Vemurafenib—Connective tissue disorder—Methylprednisolone—rheumatoid arthritis	9.85e-05	0.00178	CcSEcCtD
Vemurafenib—Decreased appetite—Leflunomide—rheumatoid arthritis	9.61e-05	0.00174	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Leflunomide—rheumatoid arthritis	9.54e-05	0.00172	CcSEcCtD
Vemurafenib—Fatigue—Leflunomide—rheumatoid arthritis	9.53e-05	0.00172	CcSEcCtD
Vemurafenib—Erythema—Prednisolone—rheumatoid arthritis	9.51e-05	0.00172	CcSEcCtD
Vemurafenib—Constipation—Leflunomide—rheumatoid arthritis	9.45e-05	0.00171	CcSEcCtD
Vemurafenib—Eye disorder—Methylprednisolone—rheumatoid arthritis	9.37e-05	0.00169	CcSEcCtD
Vemurafenib—Cardiac disorder—Methylprednisolone—rheumatoid arthritis	9.3e-05	0.00168	CcSEcCtD
Vemurafenib—Erythema—Hydrocortisone—rheumatoid arthritis	9.29e-05	0.00168	CcSEcCtD
Vemurafenib—Malnutrition—Hydrocortisone—rheumatoid arthritis	9.29e-05	0.00168	CcSEcCtD
Vemurafenib—Body temperature increased—Azathioprine—rheumatoid arthritis	9.25e-05	0.00167	CcSEcCtD
Vemurafenib—Cough—Cyclosporine—rheumatoid arthritis	9.12e-05	0.00165	CcSEcCtD
Vemurafenib—Angiopathy—Methylprednisolone—rheumatoid arthritis	9.09e-05	0.00164	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methylprednisolone—rheumatoid arthritis	9.03e-05	0.00163	CcSEcCtD
Vemurafenib—Weight decreased—Prednisone—rheumatoid arthritis	8.97e-05	0.00162	CcSEcCtD
Vemurafenib—Myalgia—Cyclosporine—rheumatoid arthritis	8.9e-05	0.00161	CcSEcCtD
Vemurafenib—Arthralgia—Cyclosporine—rheumatoid arthritis	8.9e-05	0.00161	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—rheumatoid arthritis	8.84e-05	0.0016	CcSEcCtD
Vemurafenib—Erythema—Triamcinolone—rheumatoid arthritis	8.74e-05	0.00158	CcSEcCtD
Vemurafenib—Body temperature increased—Leflunomide—rheumatoid arthritis	8.74e-05	0.00158	CcSEcCtD
Vemurafenib—Malnutrition—Methylprednisolone—rheumatoid arthritis	8.72e-05	0.00158	CcSEcCtD
Vemurafenib—Erythema—Methylprednisolone—rheumatoid arthritis	8.72e-05	0.00158	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—rheumatoid arthritis	8.67e-05	0.00157	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—rheumatoid arthritis	8.63e-05	0.00156	CcSEcCtD
Vemurafenib—Hypersensitivity—Azathioprine—rheumatoid arthritis	8.62e-05	0.00156	CcSEcCtD
Vemurafenib—Dysgeusia—Triamcinolone—rheumatoid arthritis	8.56e-05	0.00155	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cyclosporine—rheumatoid arthritis	8.53e-05	0.00154	CcSEcCtD
Vemurafenib—Eye disorder—Dexamethasone—rheumatoid arthritis	8.52e-05	0.00154	CcSEcCtD
Vemurafenib—Eye disorder—Betamethasone—rheumatoid arthritis	8.52e-05	0.00154	CcSEcCtD
Vemurafenib—Infection—Cyclosporine—rheumatoid arthritis	8.47e-05	0.00153	CcSEcCtD
Vemurafenib—Back pain—Triamcinolone—rheumatoid arthritis	8.46e-05	0.00153	CcSEcCtD
Vemurafenib—Nervous system disorder—Cyclosporine—rheumatoid arthritis	8.36e-05	0.00151	CcSEcCtD
Vemurafenib—Skin disorder—Cyclosporine—rheumatoid arthritis	8.28e-05	0.0015	CcSEcCtD
Vemurafenib—Angiopathy—Betamethasone—rheumatoid arthritis	8.27e-05	0.00149	CcSEcCtD
Vemurafenib—Angiopathy—Dexamethasone—rheumatoid arthritis	8.27e-05	0.00149	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—rheumatoid arthritis	8.21e-05	0.00148	CcSEcCtD
Vemurafenib—Hypersensitivity—Leflunomide—rheumatoid arthritis	8.14e-05	0.00147	CcSEcCtD
Vemurafenib—Alopecia—Betamethasone—rheumatoid arthritis	8.05e-05	0.00146	CcSEcCtD
Vemurafenib—Alopecia—Dexamethasone—rheumatoid arthritis	8.05e-05	0.00146	CcSEcCtD
Vemurafenib—Diarrhoea—Azathioprine—rheumatoid arthritis	8.01e-05	0.00145	CcSEcCtD
Vemurafenib—Erythema—Dexamethasone—rheumatoid arthritis	7.93e-05	0.00143	CcSEcCtD
Vemurafenib—Erythema—Betamethasone—rheumatoid arthritis	7.93e-05	0.00143	CcSEcCtD
Vemurafenib—Asthenia—Leflunomide—rheumatoid arthritis	7.93e-05	0.00143	CcSEcCtD
Vemurafenib—Myalgia—Hydrocortisone—rheumatoid arthritis	7.91e-05	0.00143	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—rheumatoid arthritis	7.85e-05	0.00142	CcSEcCtD
Vemurafenib—Pruritus—Leflunomide—rheumatoid arthritis	7.82e-05	0.00141	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—rheumatoid arthritis	7.8e-05	0.00141	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cyclosporine—rheumatoid arthritis	7.77e-05	0.0014	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisolone—rheumatoid arthritis	7.76e-05	0.0014	CcSEcCtD
Vemurafenib—Dizziness—Azathioprine—rheumatoid arthritis	7.74e-05	0.0014	CcSEcCtD
Vemurafenib—Cough—Triamcinolone—rheumatoid arthritis	7.63e-05	0.00138	CcSEcCtD
Vemurafenib—Anaphylactic shock—Hydrocortisone—rheumatoid arthritis	7.58e-05	0.00137	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—rheumatoid arthritis	7.56e-05	0.00137	CcSEcCtD
Vemurafenib—Diarrhoea—Leflunomide—rheumatoid arthritis	7.56e-05	0.00137	CcSEcCtD
Vemurafenib—Infection—Hydrocortisone—rheumatoid arthritis	7.53e-05	0.00136	CcSEcCtD
Vemurafenib—Myalgia—Triamcinolone—rheumatoid arthritis	7.44e-05	0.00135	CcSEcCtD
Vemurafenib—Vomiting—Azathioprine—rheumatoid arthritis	7.44e-05	0.00134	CcSEcCtD
Vemurafenib—Nervous system disorder—Hydrocortisone—rheumatoid arthritis	7.43e-05	0.00134	CcSEcCtD
Vemurafenib—Myalgia—Methylprednisolone—rheumatoid arthritis	7.43e-05	0.00134	CcSEcCtD
Vemurafenib—Arthralgia—Methylprednisolone—rheumatoid arthritis	7.43e-05	0.00134	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—rheumatoid arthritis	7.42e-05	0.00134	CcSEcCtD
Vemurafenib—Decreased appetite—Cyclosporine—rheumatoid arthritis	7.41e-05	0.00134	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—rheumatoid arthritis	7.39e-05	0.00134	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—rheumatoid arthritis	7.39e-05	0.00134	CcSEcCtD
Vemurafenib—Rash—Azathioprine—rheumatoid arthritis	7.38e-05	0.00133	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—rheumatoid arthritis	7.38e-05	0.00133	CcSEcCtD
Vemurafenib—Dermatitis—Azathioprine—rheumatoid arthritis	7.37e-05	0.00133	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cyclosporine—rheumatoid arthritis	7.36e-05	0.00133	CcSEcCtD
Vemurafenib—Skin disorder—Hydrocortisone—rheumatoid arthritis	7.36e-05	0.00133	CcSEcCtD
Vemurafenib—Fatigue—Cyclosporine—rheumatoid arthritis	7.35e-05	0.00133	CcSEcCtD
Vemurafenib—Headache—Azathioprine—rheumatoid arthritis	7.33e-05	0.00132	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—rheumatoid arthritis	7.33e-05	0.00132	CcSEcCtD
Vemurafenib—Dizziness—Leflunomide—rheumatoid arthritis	7.31e-05	0.00132	CcSEcCtD
Vemurafenib—Constipation—Cyclosporine—rheumatoid arthritis	7.29e-05	0.00132	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—rheumatoid arthritis	7.2e-05	0.0013	CcSEcCtD
Vemurafenib—Anaphylactic shock—Triamcinolone—rheumatoid arthritis	7.14e-05	0.00129	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methylprednisolone—rheumatoid arthritis	7.12e-05	0.00129	CcSEcCtD
Vemurafenib—Infection—Triamcinolone—rheumatoid arthritis	7.09e-05	0.00128	CcSEcCtD
Vemurafenib—Hypotension—Hydrocortisone—rheumatoid arthritis	7.08e-05	0.00128	CcSEcCtD
Vemurafenib—Infection—Methylprednisolone—rheumatoid arthritis	7.07e-05	0.00128	CcSEcCtD
Vemurafenib—Vomiting—Leflunomide—rheumatoid arthritis	7.03e-05	0.00127	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—rheumatoid arthritis	7.01e-05	0.00127	CcSEcCtD
Vemurafenib—Nervous system disorder—Methylprednisolone—rheumatoid arthritis	6.98e-05	0.00126	CcSEcCtD
Vemurafenib—Rash—Leflunomide—rheumatoid arthritis	6.97e-05	0.00126	CcSEcCtD
Vemurafenib—Dermatitis—Leflunomide—rheumatoid arthritis	6.96e-05	0.00126	CcSEcCtD
Vemurafenib—Nausea—Azathioprine—rheumatoid arthritis	6.95e-05	0.00126	CcSEcCtD
Vemurafenib—Headache—Leflunomide—rheumatoid arthritis	6.92e-05	0.00125	CcSEcCtD
Vemurafenib—Skin disorder—Methylprednisolone—rheumatoid arthritis	6.92e-05	0.00125	CcSEcCtD
Vemurafenib—Erythema—Prednisone—rheumatoid arthritis	6.91e-05	0.00125	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—rheumatoid arthritis	6.91e-05	0.00125	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Hydrocortisone—rheumatoid arthritis	6.91e-05	0.00125	CcSEcCtD
Vemurafenib—Myalgia—Dexamethasone—rheumatoid arthritis	6.75e-05	0.00122	CcSEcCtD
Vemurafenib—Myalgia—Betamethasone—rheumatoid arthritis	6.75e-05	0.00122	CcSEcCtD
Vemurafenib—Body temperature increased—Cyclosporine—rheumatoid arthritis	6.74e-05	0.00122	CcSEcCtD
Vemurafenib—Hypotension—Methylprednisolone—rheumatoid arthritis	6.65e-05	0.0012	CcSEcCtD
Vemurafenib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	6.59e-05	0.00119	CcSEcCtD
Vemurafenib—Nausea—Leflunomide—rheumatoid arthritis	6.56e-05	0.00119	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	6.54e-05	0.00118	CcSEcCtD
Vemurafenib—Fatigue—Hydrocortisone—rheumatoid arthritis	6.53e-05	0.00118	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Triamcinolone—rheumatoid arthritis	6.5e-05	0.00117	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methylprednisolone—rheumatoid arthritis	6.49e-05	0.00117	CcSEcCtD
Vemurafenib—Anaphylactic shock—Dexamethasone—rheumatoid arthritis	6.48e-05	0.00117	CcSEcCtD
Vemurafenib—Anaphylactic shock—Betamethasone—rheumatoid arthritis	6.48e-05	0.00117	CcSEcCtD
Vemurafenib—Infection—Betamethasone—rheumatoid arthritis	6.43e-05	0.00116	CcSEcCtD
Vemurafenib—Infection—Dexamethasone—rheumatoid arthritis	6.43e-05	0.00116	CcSEcCtD
Vemurafenib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	6.35e-05	0.00115	CcSEcCtD
Vemurafenib—Nervous system disorder—Betamethasone—rheumatoid arthritis	6.35e-05	0.00115	CcSEcCtD
Vemurafenib—Hypersensitivity—Cyclosporine—rheumatoid arthritis	6.28e-05	0.00114	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—rheumatoid arthritis	6.27e-05	0.00113	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—rheumatoid arthritis	6.2e-05	0.00112	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—rheumatoid arthritis	6.16e-05	0.00111	CcSEcCtD
Vemurafenib—Fatigue—Triamcinolone—rheumatoid arthritis	6.15e-05	0.00111	CcSEcCtD
Vemurafenib—Fatigue—Methylprednisolone—rheumatoid arthritis	6.14e-05	0.00111	CcSEcCtD
Vemurafenib—Asthenia—Cyclosporine—rheumatoid arthritis	6.12e-05	0.00111	CcSEcCtD
Vemurafenib—Hypotension—Dexamethasone—rheumatoid arthritis	6.05e-05	0.00109	CcSEcCtD
Vemurafenib—Hypotension—Betamethasone—rheumatoid arthritis	6.05e-05	0.00109	CcSEcCtD
Vemurafenib—Pruritus—Cyclosporine—rheumatoid arthritis	6.03e-05	0.00109	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—rheumatoid arthritis	6.02e-05	0.00109	CcSEcCtD
Vemurafenib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	5.99e-05	0.00108	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	5.98e-05	0.00108	CcSEcCtD
Vemurafenib—Chills—Methotrexate—rheumatoid arthritis	5.95e-05	0.00108	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Betamethasone—rheumatoid arthritis	5.9e-05	0.00107	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dexamethasone—rheumatoid arthritis	5.9e-05	0.00107	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—rheumatoid arthritis	5.88e-05	0.00106	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—rheumatoid arthritis	5.88e-05	0.00106	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—rheumatoid arthritis	5.86e-05	0.00106	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	5.84e-05	0.00106	CcSEcCtD
Vemurafenib—Diarrhoea—Cyclosporine—rheumatoid arthritis	5.84e-05	0.00105	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—rheumatoid arthritis	5.77e-05	0.00104	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—rheumatoid arthritis	5.77e-05	0.00104	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisolone—rheumatoid arthritis	5.72e-05	0.00103	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—rheumatoid arthritis	5.65e-05	0.00102	CcSEcCtD
Vemurafenib—Body temperature increased—Triamcinolone—rheumatoid arthritis	5.64e-05	0.00102	CcSEcCtD
Vemurafenib—Dizziness—Cyclosporine—rheumatoid arthritis	5.64e-05	0.00102	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—rheumatoid arthritis	5.64e-05	0.00102	CcSEcCtD
Vemurafenib—Decreased appetite—Dexamethasone—rheumatoid arthritis	5.63e-05	0.00102	CcSEcCtD
Vemurafenib—Decreased appetite—Betamethasone—rheumatoid arthritis	5.63e-05	0.00102	CcSEcCtD
Vemurafenib—Infection—Prednisone—rheumatoid arthritis	5.6e-05	0.00101	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	5.59e-05	0.00101	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	5.59e-05	0.00101	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—rheumatoid arthritis	5.59e-05	0.00101	CcSEcCtD
Vemurafenib—Hypersensitivity—Hydrocortisone—rheumatoid arthritis	5.58e-05	0.00101	CcSEcCtD
Vemurafenib—Fatigue—Dexamethasone—rheumatoid arthritis	5.58e-05	0.00101	CcSEcCtD
Vemurafenib—Fatigue—Betamethasone—rheumatoid arthritis	5.58e-05	0.00101	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—rheumatoid arthritis	5.53e-05	0.000999	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—rheumatoid arthritis	5.48e-05	0.00099	CcSEcCtD
Vemurafenib—Asthenia—Hydrocortisone—rheumatoid arthritis	5.44e-05	0.000983	CcSEcCtD
Vemurafenib—Vomiting—Cyclosporine—rheumatoid arthritis	5.42e-05	0.00098	CcSEcCtD
Vemurafenib—Rash—Cyclosporine—rheumatoid arthritis	5.38e-05	0.000972	CcSEcCtD
Vemurafenib—Dermatitis—Cyclosporine—rheumatoid arthritis	5.37e-05	0.000971	CcSEcCtD
Vemurafenib—Pruritus—Hydrocortisone—rheumatoid arthritis	5.36e-05	0.000969	CcSEcCtD
Vemurafenib—Headache—Cyclosporine—rheumatoid arthritis	5.34e-05	0.000965	CcSEcCtD
Vemurafenib—Hypersensitivity—Triamcinolone—rheumatoid arthritis	5.26e-05	0.00095	CcSEcCtD
Vemurafenib—Hypersensitivity—Methylprednisolone—rheumatoid arthritis	5.25e-05	0.000948	CcSEcCtD
Vemurafenib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	5.19e-05	0.000937	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—rheumatoid arthritis	5.14e-05	0.000928	CcSEcCtD
Vemurafenib—Dizziness—Prednisolone—rheumatoid arthritis	5.13e-05	0.000927	CcSEcCtD
Vemurafenib—Asthenia—Triamcinolone—rheumatoid arthritis	5.12e-05	0.000925	CcSEcCtD
Vemurafenib—Body temperature increased—Dexamethasone—rheumatoid arthritis	5.12e-05	0.000925	CcSEcCtD
Vemurafenib—Body temperature increased—Betamethasone—rheumatoid arthritis	5.12e-05	0.000925	CcSEcCtD
Vemurafenib—Asthenia—Methylprednisolone—rheumatoid arthritis	5.11e-05	0.000923	CcSEcCtD
Vemurafenib—Nausea—Cyclosporine—rheumatoid arthritis	5.07e-05	0.000915	CcSEcCtD
Vemurafenib—Pruritus—Triamcinolone—rheumatoid arthritis	5.05e-05	0.000912	CcSEcCtD
Vemurafenib—Cough—Methotrexate—rheumatoid arthritis	5.04e-05	0.00091	CcSEcCtD
Vemurafenib—Pruritus—Methylprednisolone—rheumatoid arthritis	5.04e-05	0.00091	CcSEcCtD
Vemurafenib—Dizziness—Hydrocortisone—rheumatoid arthritis	5.01e-05	0.000906	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—rheumatoid arthritis	4.92e-05	0.000888	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—rheumatoid arthritis	4.92e-05	0.000888	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—rheumatoid arthritis	4.9e-05	0.000886	CcSEcCtD
Vemurafenib—Rash—Prednisolone—rheumatoid arthritis	4.89e-05	0.000884	CcSEcCtD
Vemurafenib—Dermatitis—Prednisolone—rheumatoid arthritis	4.89e-05	0.000883	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	4.88e-05	0.000882	CcSEcCtD
Vemurafenib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	4.87e-05	0.00088	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—rheumatoid arthritis	4.86e-05	0.000878	CcSEcCtD
Vemurafenib—Headache—Prednisolone—rheumatoid arthritis	4.86e-05	0.000878	CcSEcCtD
Vemurafenib—Constipation—Prednisone—rheumatoid arthritis	4.82e-05	0.000871	CcSEcCtD
Vemurafenib—Vomiting—Hydrocortisone—rheumatoid arthritis	4.82e-05	0.000871	CcSEcCtD
Vemurafenib—Rash—Hydrocortisone—rheumatoid arthritis	4.78e-05	0.000863	CcSEcCtD
Vemurafenib—Dermatitis—Hydrocortisone—rheumatoid arthritis	4.77e-05	0.000863	CcSEcCtD
Vemurafenib—Headache—Hydrocortisone—rheumatoid arthritis	4.75e-05	0.000858	CcSEcCtD
Vemurafenib—Dizziness—Triamcinolone—rheumatoid arthritis	4.72e-05	0.000853	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—rheumatoid arthritis	4.71e-05	0.000852	CcSEcCtD
Vemurafenib—Dizziness—Methylprednisolone—rheumatoid arthritis	4.71e-05	0.000851	CcSEcCtD
Vemurafenib—Infection—Methotrexate—rheumatoid arthritis	4.68e-05	0.000846	CcSEcCtD
Vemurafenib—Asthenia—Betamethasone—rheumatoid arthritis	4.65e-05	0.000839	CcSEcCtD
Vemurafenib—Asthenia—Dexamethasone—rheumatoid arthritis	4.65e-05	0.000839	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—rheumatoid arthritis	4.62e-05	0.000835	CcSEcCtD
Vemurafenib—Nausea—Prednisolone—rheumatoid arthritis	4.61e-05	0.000833	CcSEcCtD
Vemurafenib—Pruritus—Dexamethasone—rheumatoid arthritis	4.58e-05	0.000828	CcSEcCtD
Vemurafenib—Pruritus—Betamethasone—rheumatoid arthritis	4.58e-05	0.000828	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—rheumatoid arthritis	4.58e-05	0.000827	CcSEcCtD
Vemurafenib—Vomiting—Triamcinolone—rheumatoid arthritis	4.54e-05	0.00082	CcSEcCtD
Vemurafenib—Vomiting—Methylprednisolone—rheumatoid arthritis	4.53e-05	0.000818	CcSEcCtD
Vemurafenib—Nausea—Hydrocortisone—rheumatoid arthritis	4.5e-05	0.000813	CcSEcCtD
Vemurafenib—Rash—Triamcinolone—rheumatoid arthritis	4.5e-05	0.000813	CcSEcCtD
Vemurafenib—Dermatitis—Triamcinolone—rheumatoid arthritis	4.5e-05	0.000812	CcSEcCtD
Vemurafenib—Rash—Methylprednisolone—rheumatoid arthritis	4.49e-05	0.000811	CcSEcCtD
Vemurafenib—Dermatitis—Methylprednisolone—rheumatoid arthritis	4.49e-05	0.00081	CcSEcCtD
Vemurafenib—Headache—Triamcinolone—rheumatoid arthritis	4.47e-05	0.000808	CcSEcCtD
Vemurafenib—Headache—Methylprednisolone—rheumatoid arthritis	4.46e-05	0.000806	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—rheumatoid arthritis	4.46e-05	0.000805	CcSEcCtD
Vemurafenib—Diarrhoea—Betamethasone—rheumatoid arthritis	4.43e-05	0.000801	CcSEcCtD
Vemurafenib—Diarrhoea—Dexamethasone—rheumatoid arthritis	4.43e-05	0.000801	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—rheumatoid arthritis	4.4e-05	0.000796	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—rheumatoid arthritis	4.29e-05	0.000776	CcSEcCtD
Vemurafenib—Dizziness—Betamethasone—rheumatoid arthritis	4.28e-05	0.000774	CcSEcCtD
Vemurafenib—Dizziness—Dexamethasone—rheumatoid arthritis	4.28e-05	0.000774	CcSEcCtD
Vemurafenib—Nausea—Triamcinolone—rheumatoid arthritis	4.24e-05	0.000766	CcSEcCtD
Vemurafenib—Nausea—Methylprednisolone—rheumatoid arthritis	4.23e-05	0.000764	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—rheumatoid arthritis	4.15e-05	0.000751	CcSEcCtD
Vemurafenib—Vomiting—Dexamethasone—rheumatoid arthritis	4.12e-05	0.000744	CcSEcCtD
Vemurafenib—Vomiting—Betamethasone—rheumatoid arthritis	4.12e-05	0.000744	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—rheumatoid arthritis	4.1e-05	0.00074	CcSEcCtD
Vemurafenib—Rash—Betamethasone—rheumatoid arthritis	4.08e-05	0.000738	CcSEcCtD
Vemurafenib—Rash—Dexamethasone—rheumatoid arthritis	4.08e-05	0.000738	CcSEcCtD
Vemurafenib—Dermatitis—Betamethasone—rheumatoid arthritis	4.08e-05	0.000737	CcSEcCtD
Vemurafenib—Dermatitis—Dexamethasone—rheumatoid arthritis	4.08e-05	0.000737	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	4.07e-05	0.000735	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—rheumatoid arthritis	4.06e-05	0.000734	CcSEcCtD
Vemurafenib—Headache—Dexamethasone—rheumatoid arthritis	4.06e-05	0.000733	CcSEcCtD
Vemurafenib—Headache—Betamethasone—rheumatoid arthritis	4.06e-05	0.000733	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—rheumatoid arthritis	4.05e-05	0.000731	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—rheumatoid arthritis	3.99e-05	0.000721	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—rheumatoid arthritis	3.86e-05	0.000697	CcSEcCtD
Vemurafenib—Nausea—Betamethasone—rheumatoid arthritis	3.85e-05	0.000695	CcSEcCtD
Vemurafenib—Nausea—Dexamethasone—rheumatoid arthritis	3.85e-05	0.000695	CcSEcCtD
Vemurafenib—Dizziness—Prednisone—rheumatoid arthritis	3.73e-05	0.000674	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—rheumatoid arthritis	3.73e-05	0.000673	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—rheumatoid arthritis	3.59e-05	0.000648	CcSEcCtD
Vemurafenib—Rash—Prednisone—rheumatoid arthritis	3.56e-05	0.000642	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—rheumatoid arthritis	3.55e-05	0.000642	CcSEcCtD
Vemurafenib—Headache—Prednisone—rheumatoid arthritis	3.53e-05	0.000638	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—rheumatoid arthritis	3.47e-05	0.000627	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—rheumatoid arthritis	3.38e-05	0.000611	CcSEcCtD
Vemurafenib—Nausea—Prednisone—rheumatoid arthritis	3.35e-05	0.000605	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—rheumatoid arthritis	3.33e-05	0.000602	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—rheumatoid arthritis	3.22e-05	0.000583	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—rheumatoid arthritis	3.12e-05	0.000563	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—rheumatoid arthritis	3e-05	0.000541	CcSEcCtD
Vemurafenib—Rash—Methotrexate—rheumatoid arthritis	2.97e-05	0.000537	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—rheumatoid arthritis	2.97e-05	0.000536	CcSEcCtD
Vemurafenib—Headache—Methotrexate—rheumatoid arthritis	2.95e-05	0.000533	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—rheumatoid arthritis	2.8e-05	0.000506	CcSEcCtD
Vemurafenib—ALB—Hemostasis—CSF2—rheumatoid arthritis	6.53e-06	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1A—rheumatoid arthritis	6.47e-06	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL18—rheumatoid arthritis	6.46e-06	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL2—rheumatoid arthritis	6.46e-06	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL3—rheumatoid arthritis	6.46e-06	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40LG—rheumatoid arthritis	6.44e-06	0.0001	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2—rheumatoid arthritis	6.41e-06	0.0001	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP3—rheumatoid arthritis	6.4e-06	9.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD80—rheumatoid arthritis	6.39e-06	9.97e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ENO1—rheumatoid arthritis	6.39e-06	9.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCR5—rheumatoid arthritis	6.37e-06	9.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—rheumatoid arthritis	6.36e-06	9.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CSF2—rheumatoid arthritis	6.36e-06	9.93e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GC—rheumatoid arthritis	6.36e-06	9.92e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGES—rheumatoid arthritis	6.36e-06	9.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SAA1—rheumatoid arthritis	6.32e-06	9.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2RA—rheumatoid arthritis	6.28e-06	9.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—rheumatoid arthritis	6.28e-06	9.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MED1—rheumatoid arthritis	6.28e-06	9.8e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	6.25e-06	9.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—C3—rheumatoid arthritis	6.23e-06	9.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AGER—rheumatoid arthritis	6.21e-06	9.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—rheumatoid arthritis	6.19e-06	9.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NCF1—rheumatoid arthritis	6.18e-06	9.65e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTK2—rheumatoid arthritis	6.16e-06	9.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NFKB1—rheumatoid arthritis	6.12e-06	9.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-B—rheumatoid arthritis	6.12e-06	9.56e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLD4—rheumatoid arthritis	6.1e-06	9.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—rheumatoid arthritis	6.05e-06	9.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL5—rheumatoid arthritis	6.04e-06	9.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—rheumatoid arthritis	6.03e-06	9.41e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—POMC—rheumatoid arthritis	5.98e-06	9.33e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	5.97e-06	9.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—rheumatoid arthritis	5.95e-06	9.29e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CSF2—rheumatoid arthritis	5.95e-06	9.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD28—rheumatoid arthritis	5.95e-06	9.28e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6R—rheumatoid arthritis	5.92e-06	9.24e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLB1—rheumatoid arthritis	5.91e-06	9.22e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2RA—rheumatoid arthritis	5.89e-06	9.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ACAN—rheumatoid arthritis	5.89e-06	9.19e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—B3GNT2—rheumatoid arthritis	5.83e-06	9.11e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ACP5—rheumatoid arthritis	5.83e-06	9.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2RA—rheumatoid arthritis	5.74e-06	8.95e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—rheumatoid arthritis	5.69e-06	8.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—C3—rheumatoid arthritis	5.69e-06	8.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-A—rheumatoid arthritis	5.67e-06	8.85e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MMP1—rheumatoid arthritis	5.62e-06	8.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—UBE2D1—rheumatoid arthritis	5.6e-06	8.74e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SPP1—rheumatoid arthritis	5.59e-06	8.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—rheumatoid arthritis	5.56e-06	8.67e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC25A12—rheumatoid arthritis	5.54e-06	8.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BDKRB2—rheumatoid arthritis	5.49e-06	8.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL12—rheumatoid arthritis	5.49e-06	8.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—rheumatoid arthritis	5.45e-06	8.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6ST—rheumatoid arthritis	5.44e-06	8.5e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCR5—rheumatoid arthritis	5.44e-06	8.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADRBK1—rheumatoid arthritis	5.43e-06	8.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CRP—rheumatoid arthritis	5.41e-06	8.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NFKB1—rheumatoid arthritis	5.41e-06	8.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TYK2—rheumatoid arthritis	5.39e-06	8.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—rheumatoid arthritis	5.39e-06	8.41e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGES—rheumatoid arthritis	5.38e-06	8.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GC—rheumatoid arthritis	5.38e-06	8.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CCR5—rheumatoid arthritis	5.37e-06	8.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2RA—rheumatoid arthritis	5.36e-06	8.37e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CCR5—rheumatoid arthritis	5.33e-06	8.32e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—C3—rheumatoid arthritis	5.32e-06	8.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MAPK8—rheumatoid arthritis	5.32e-06	8.3e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS3—rheumatoid arthritis	5.29e-06	8.26e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—BGN—rheumatoid arthritis	5.25e-06	8.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—rheumatoid arthritis	5.25e-06	8.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HLA-A—rheumatoid arthritis	5.24e-06	8.18e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—rheumatoid arthritis	5.22e-06	8.15e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CAT—rheumatoid arthritis	5.22e-06	8.15e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—rheumatoid arthritis	5.21e-06	8.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NFKB1—rheumatoid arthritis	5.19e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HLA-A—rheumatoid arthritis	5.19e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TLR4—rheumatoid arthritis	5.19e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DRB1—rheumatoid arthritis	5.18e-06	8.09e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MED1—rheumatoid arthritis	5.18e-06	8.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—FN1—rheumatoid arthritis	5.13e-06	8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RASGRP1—rheumatoid arthritis	5.12e-06	7.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SYK—rheumatoid arthritis	5.11e-06	7.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—rheumatoid arthritis	5.1e-06	7.96e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS2—rheumatoid arthritis	5.07e-06	7.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PRKCQ—rheumatoid arthritis	5.01e-06	7.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLB1—rheumatoid arthritis	5.01e-06	7.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—rheumatoid arthritis	5e-06	7.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—POMC—rheumatoid arthritis	4.98e-06	7.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ICAM1—rheumatoid arthritis	4.97e-06	7.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6ST—rheumatoid arthritis	4.97e-06	7.76e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—LEP—rheumatoid arthritis	4.95e-06	7.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT1—rheumatoid arthritis	4.92e-06	7.68e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—rheumatoid arthritis	4.88e-06	7.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL2—rheumatoid arthritis	4.87e-06	7.6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6R—rheumatoid arthritis	4.86e-06	7.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL10—rheumatoid arthritis	4.85e-06	7.58e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—rheumatoid arthritis	4.84e-06	7.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ALOX5—rheumatoid arthritis	4.83e-06	7.55e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ACP5—rheumatoid arthritis	4.82e-06	7.52e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—B3GNT2—rheumatoid arthritis	4.82e-06	7.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD80—rheumatoid arthritis	4.79e-06	7.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—rheumatoid arthritis	4.76e-06	7.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLD4—rheumatoid arthritis	4.7e-06	7.34e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FN1—rheumatoid arthritis	4.67e-06	7.28e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6ST—rheumatoid arthritis	4.65e-06	7.26e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CAT—rheumatoid arthritis	4.6e-06	7.18e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6ST—rheumatoid arthritis	4.59e-06	7.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS2—rheumatoid arthritis	4.56e-06	7.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6ST—rheumatoid arthritis	4.55e-06	7.11e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ACAN—rheumatoid arthritis	4.54e-06	7.09e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS2—rheumatoid arthritis	4.52e-06	7.05e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CD80—rheumatoid arthritis	4.47e-06	6.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6R—rheumatoid arthritis	4.44e-06	6.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP3—rheumatoid arthritis	4.43e-06	6.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TYK2—rheumatoid arthritis	4.42e-06	6.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD80—rheumatoid arthritis	4.42e-06	6.9e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MED1—rheumatoid arthritis	4.39e-06	6.85e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD80—rheumatoid arthritis	4.38e-06	6.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—rheumatoid arthritis	4.36e-06	6.81e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—BGN—rheumatoid arthritis	4.34e-06	6.77e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC25A12—rheumatoid arthritis	4.27e-06	6.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTK2—rheumatoid arthritis	4.26e-06	6.65e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—POMC—rheumatoid arthritis	4.25e-06	6.64e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	4.25e-06	6.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL5—rheumatoid arthritis	4.18e-06	6.52e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL2—rheumatoid arthritis	4.16e-06	6.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGES—rheumatoid arthritis	4.16e-06	6.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GC—rheumatoid arthritis	4.16e-06	6.49e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6R—rheumatoid arthritis	4.15e-06	6.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—rheumatoid arthritis	4.12e-06	6.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CSF2—rheumatoid arthritis	4.11e-06	6.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6R—rheumatoid arthritis	4.1e-06	6.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—B3GNT2—rheumatoid arthritis	4.08e-06	6.37e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ACP5—rheumatoid arthritis	4.08e-06	6.37e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS3—rheumatoid arthritis	4.07e-06	6.36e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6R—rheumatoid arthritis	4.06e-06	6.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TYK2—rheumatoid arthritis	4.04e-06	6.31e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALOX5—rheumatoid arthritis	3.99e-06	6.23e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO1—rheumatoid arthritis	3.94e-06	6.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SPP1—rheumatoid arthritis	3.87e-06	6.04e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLB1—rheumatoid arthritis	3.86e-06	6.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—rheumatoid arthritis	3.85e-06	6.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—rheumatoid arthritis	3.84e-06	6e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—rheumatoid arthritis	3.84e-06	5.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—rheumatoid arthritis	3.78e-06	5.91e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TYK2—rheumatoid arthritis	3.78e-06	5.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR5—rheumatoid arthritis	3.76e-06	5.87e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TYK2—rheumatoid arthritis	3.73e-06	5.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2RA—rheumatoid arthritis	3.71e-06	5.79e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOS3—rheumatoid arthritis	3.71e-06	5.79e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TYK2—rheumatoid arthritis	3.7e-06	5.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—rheumatoid arthritis	3.68e-06	5.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—C3—rheumatoid arthritis	3.68e-06	5.74e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BGN—rheumatoid arthritis	3.67e-06	5.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS3—rheumatoid arthritis	3.66e-06	5.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—rheumatoid arthritis	3.66e-06	5.71e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS3—rheumatoid arthritis	3.63e-06	5.67e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—rheumatoid arthritis	3.5e-06	5.46e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—POMC—rheumatoid arthritis	3.49e-06	5.44e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—rheumatoid arthritis	3.45e-06	5.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LEP—rheumatoid arthritis	3.42e-06	5.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—rheumatoid arthritis	3.39e-06	5.3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	3.39e-06	5.29e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MED1—rheumatoid arthritis	3.39e-06	5.29e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALOX5—rheumatoid arthritis	3.38e-06	5.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—rheumatoid arthritis	3.38e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—rheumatoid arthritis	3.38e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—rheumatoid arthritis	3.36e-06	5.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—rheumatoid arthritis	3.35e-06	5.23e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—rheumatoid arthritis	3.35e-06	5.22e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—rheumatoid arthritis	3.32e-06	5.18e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—rheumatoid arthritis	3.29e-06	5.13e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO1—rheumatoid arthritis	3.25e-06	5.08e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FN1—rheumatoid arthritis	3.23e-06	5.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6ST—rheumatoid arthritis	3.22e-06	5.02e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—rheumatoid arthritis	3.18e-06	4.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NFKB1—rheumatoid arthritis	3.15e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ACP5—rheumatoid arthritis	3.15e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—B3GNT2—rheumatoid arthritis	3.15e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—rheumatoid arthritis	3.14e-06	4.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK8—rheumatoid arthritis	3.1e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD80—rheumatoid arthritis	3.1e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—POMC—rheumatoid arthritis	3.07e-06	4.79e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—rheumatoid arthritis	3.04e-06	4.75e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—rheumatoid arthritis	2.97e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	2.97e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NFKB1—rheumatoid arthritis	2.94e-06	4.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—POMC—rheumatoid arthritis	2.94e-06	4.59e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—rheumatoid arthritis	2.93e-06	4.58e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK8—rheumatoid arthritis	2.89e-06	4.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—rheumatoid arthritis	2.88e-06	4.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6R—rheumatoid arthritis	2.87e-06	4.48e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAT—rheumatoid arthritis	2.84e-06	4.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BGN—rheumatoid arthritis	2.84e-06	4.43e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—rheumatoid arthritis	2.8e-06	4.37e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—rheumatoid arthritis	2.78e-06	4.34e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO1—rheumatoid arthritis	2.76e-06	4.3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	2.71e-06	4.23e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—rheumatoid arthritis	2.69e-06	4.2e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—rheumatoid arthritis	2.68e-06	4.18e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—rheumatoid arthritis	2.67e-06	4.17e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—rheumatoid arthritis	2.64e-06	4.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TYK2—rheumatoid arthritis	2.61e-06	4.08e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALOX5—rheumatoid arthritis	2.61e-06	4.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—rheumatoid arthritis	2.57e-06	4e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—rheumatoid arthritis	2.45e-06	3.83e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—rheumatoid arthritis	2.45e-06	3.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—rheumatoid arthritis	2.42e-06	3.78e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—rheumatoid arthritis	2.4e-06	3.75e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	2.37e-06	3.7e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—rheumatoid arthritis	2.37e-06	3.7e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAT—rheumatoid arthritis	2.34e-06	3.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—rheumatoid arthritis	2.28e-06	3.55e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—rheumatoid arthritis	2.22e-06	3.46e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—rheumatoid arthritis	2.17e-06	3.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—rheumatoid arthritis	2.16e-06	3.38e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO1—rheumatoid arthritis	2.13e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—rheumatoid arthritis	2.06e-06	3.21e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKB1—rheumatoid arthritis	2.04e-06	3.18e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—rheumatoid arthritis	2.02e-06	3.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK8—rheumatoid arthritis	2e-06	3.12e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAT—rheumatoid arthritis	1.98e-06	3.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—rheumatoid arthritis	1.98e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—rheumatoid arthritis	1.95e-06	3.05e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—POMC—rheumatoid arthritis	1.89e-06	2.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—rheumatoid arthritis	1.85e-06	2.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—rheumatoid arthritis	1.85e-06	2.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—rheumatoid arthritis	1.83e-06	2.85e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—rheumatoid arthritis	1.81e-06	2.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—rheumatoid arthritis	1.7e-06	2.65e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—rheumatoid arthritis	1.66e-06	2.58e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—rheumatoid arthritis	1.65e-06	2.58e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—POMC—rheumatoid arthritis	1.56e-06	2.44e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAT—rheumatoid arthritis	1.53e-06	2.39e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—rheumatoid arthritis	1.51e-06	2.36e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—rheumatoid arthritis	1.43e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—rheumatoid arthritis	1.4e-06	2.18e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—rheumatoid arthritis	1.36e-06	2.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—POMC—rheumatoid arthritis	1.32e-06	2.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—rheumatoid arthritis	1.28e-06	2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—rheumatoid arthritis	1.28e-06	1.99e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—rheumatoid arthritis	1.25e-06	1.95e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—rheumatoid arthritis	1.21e-06	1.88e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—rheumatoid arthritis	1.15e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—rheumatoid arthritis	1.06e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—POMC—rheumatoid arthritis	1.02e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—rheumatoid arthritis	9.32e-07	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—rheumatoid arthritis	8.91e-07	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—rheumatoid arthritis	8.15e-07	1.27e-05	CbGpPWpGaD
